Futura Medical PLC
29 September 2026
29 September 2026
Futura Medical plc
("Futura", "the Company" or “the Group”)
PDMR Dealing
Futura Medical (AIM:FUM), the consumer healthcare group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that pursuant to the completion of the recent fundraise, the Directors of the Company subscribed for 23,500,000 Subscription Shares.
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Alexander Duggan | ||||
|
2 |
Reason for the notification | |||||
|
a) |
Position/status |
Chief Executive Officer | ||||
|
b) |
Initial notification/Amendment |
Initial notification | ||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name |
Futura Medical plc | ||||
|
b) |
LEI |
21380053QLT46UNV2303 | ||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares at 0.2p each
GB0033278473 | ||||
|
b) |
Nature of the transaction |
Purchase of ordinary shares
| ||||
|
c) |
Price(s) and volume(s)
|
| ||||
|
d) |
Aggregated information - Aggregated volume - Price |
12,500,000 £25,000 | ||||
|
e) |
Date of the transaction |
25 September 2026 | ||||
|
f) |
Place of the transaction |
London Stock Exchange | ||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Andrew Unitt | ||||
|
2 |
Reason for the notification | |||||
|
a) |
Position/status |
Non-Executive Chairman | ||||
|
b) |
Initial notification/Amendment |
Initial notification | ||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name |
Futura Medical plc | ||||
|
b) |
LEI |
21380053QLT46UNV2303 | ||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares at 0.2p each
GB0033278473 | ||||
|
b) |
Nature of the transaction |
Purchase of ordinary shares
| ||||
|
c) |
Price(s) and volume(s)
|
| ||||
|
d) |
Aggregated information - Aggregated volume - Price |
6,000,000 £12,000 | ||||
|
e) |
Date of the transaction |
25 September 2026 | ||||
|
f) |
Place of the transaction |
London Stock Exchange | ||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Roy Davis | ||||
|
2 |
Reason for the notification | |||||
|
a) |
Position/status |
Non-Executive Director | ||||
|
b) |
Initial notification/Amendment |
Initial notification | ||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name |
Futura Medical plc | ||||
|
b) |
LEI |
21380053QLT46UNV2303 | ||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares at 0.2p each
GB0033278473 | ||||
|
b) |
Nature of the transaction |
Purchase of ordinary shares
| ||||
|
c) |
Price(s) and volume(s)
|
| ||||
|
d) |
Aggregated information - Aggregated volume - Price |
2,500,000 £5,000 | ||||
|
e) |
Date of the transaction |
25 September 2026 | ||||
|
f) |
Place of the transaction |
London Stock Exchange | ||||
|
1 |
Details of the person discharging managerial responsibilities/person closely associated | |||||
|
a) |
Name |
Ken James | ||||
|
2 |
Reason for the notification | |||||
|
a) |
Position/status |
Executive Director and Head of R&D | ||||
|
b) |
Initial notification/Amendment |
Initial notification | ||||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
|
a) |
Name |
Futura Medical plc | ||||
|
b) |
LEI |
21380053QLT46UNV2303 | ||||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
|
a) |
Description of the financial instrument, type of instrument
Identification code |
Ordinary shares at 0.2p each
GB0033278473 | ||||
|
b) |
Nature of the transaction |
Purchase of ordinary shares
| ||||
|
c) |
Price(s) and volume(s)
|
| ||||
|
d) |
Aggregated information - Aggregated volume - Price |
2,500,000 £5,000 | ||||
|
e) |
Date of the transaction |
25 September 2026 | ||||
|
f) |
Place of the transaction |
London Stock Exchange | ||||
- ENDS –
Contacts:
|
Futura Medical plc
|
Alexander Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
investor.relations@futuramedical.com +44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Joint Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0) 20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd -Joint Broker and Retail Offer Coordinator |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0) 20 3405 0205 futura@almastrategic.com |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for Futura's development female sexual health portfolio, starting with the creation of a range of topical gels under Futura's unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication, ability to orgasm and overall sexual satisfaction.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.